Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Average Target Price of $137.31

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $142.56.

Several equities analysts have commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, July 2nd. Citigroup reaffirmed a “buy” rating and set a $160.00 price objective (up from $145.00) on shares of Mirum Pharmaceuticals in a research report on Monday. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. TD Cowen decreased their target price on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, Royal Bank Of Canada lowered their target price on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th.

Mirum Pharmaceuticals Stock Down 2.4%

Shares of NASDAQ:MIRM opened at $85.48 on Friday. The firm has a market capitalization of $5.55 billion, a PE ratio of -5.87 and a beta of 0.49. Mirum Pharmaceuticals has a 1 year low of $63.23 and a 1 year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The firm’s 50-day moving average is $99.16 and its two-hundred day moving average is $101.42.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. During the same period in the previous year, the business posted ($0.12) EPS. The company’s revenue for the quarter was up 37.9% compared to the same quarter last year. Analysts predict that Mirum Pharmaceuticals will post -1.31 EPS for the current year.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Positive Phase 3 data for brelovitug: Mirum said brelovitug met the primary endpoint in the AZURE-1 study for chronic hepatitis delta virus, reporting strong virologic response and alanine aminotransferase normalization rates. The result strengthens the company’s pipeline and potential future growth. Mirum’s Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
• Positive Sentiment: FDA approval for Atebrioz: Mirum reportedly received FDA approval for Atebrioz, adding a regulatory milestone that could support commercial revenue and broaden the company’s product portfolio. Mirum wins FDA approval for Atebrioz
• Positive Sentiment: HC Wainwright raised its long-term earnings outlook and maintained a Buy rating with a $195 price target. Its EPS forecasts increased for fiscal 2027 to $1.42, fiscal 2028 to $5.38, fiscal 2029 to $7.21, and fiscal 2030 to $10.03. Baird also raised its target to $130 and maintained an Outperform rating. Mirum Pharmaceuticals Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: Analyst estimates remain mixed in the near term: HC Wainwright raised its Q3 2026 EPS forecast from a loss of $0.31 to positive $0.07 and slightly improved its Q4 2026 estimate, but reduced its Q3 2027 forecast to $0.35 from $0.40. The firm still expects Mirum to report a full-year loss of $1.31.
• Neutral Sentiment: An investor survey comparing Mirum with Sarepta Therapeutics provides additional market commentary but does not represent a material change to Mirum’s fundamentals. Mirum Pharmaceuticals and Sarepta Therapeutics Head-To-Head Survey

Insider Activity

In related news, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total value of $2,960,400.00. Following the sale, the chief executive officer owned 194,440 shares of the company’s stock, valued at $19,187,339.20. This trade represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the completion of the sale, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 123,499 shares of company stock worth $12,854,484. 8.32% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of large investors have recently modified their holdings of MIRM. Jupiter Topco LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter valued at $691,672,000. Janus Henderson Group PLC grew its stake in shares of Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after purchasing an additional 880,505 shares in the last quarter. BlackRock Inc. purchased a new position in Mirum Pharmaceuticals in the second quarter valued at $513,945,000. ABS Investment Management LLC purchased a new position in Mirum Pharmaceuticals in the second quarter valued at $245,847,000. Finally, William Blair Investment Management LLC acquired a new stake in Mirum Pharmaceuticals in the second quarter valued at $164,453,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.